
- Articles
CMA publishes updated guidance on collaboration between higher education providers
13 Apr 2026The CMA has issued updated guidance clarifying how higher education providers can collaborate while remaining compliant with UK competition law.

- Articles
Contractual controls - what they are and what it means
14 Apr 2026The government has published draft Provision of Information (Contractual Controls) (Registered Land) Regulations 2026 ("the Regulations") demonstrating its intention to introduce a new transparency regime for “contractual controls” over registered land.

- Articles
Manufacturing investment announcements paint exciting future for UK life sciences
20 Apr 2026Three pharma manufacturing investments of over £80 million have dramatically boosted UK life sciences prospects. They support the Life Sciences Sector Plan, which looks to make the UK the number one life sciences economy in Europe by 2030 and third in the world by 2035.

- Articles
Unlocking innovation for brain tumours
05 May 2026The Brain Tumour Charity has released a powerful report that highlights the urgent need for innovation in brain tumour treatments. Brain tumours remain the leading cancer killer of children and adults under 40, yet the pace of progress in developing new treatments has been alarmingly slow. The report identifies critical barriers to innovation and offers eight actionable recommendations to address these challenges.

- Articles
Unlocking development sites: land appropriation explained
08 May 2026Land appropriation is increasingly being used by local authorities and developers to unlock sites for development. In this article, we explain how the appropriation process works, the statutory framework behind it, and how Section 203 powers can assist where development is affected by private third-party rights.

- Articles
Operation Pangea XVIII: What the UK’s largest medicines seizure means for the Pharma Sector
27 May 2026Over two million doses. £4.6 million. Just 14 days. The results from Operation Pangea XVIII are striking with important implications for businesses operating in the UK pharmaceutical supply chain.